Estrogen suppresses hepatocellular carcinoma cells through ERβ-mediated upregulation of the NLRP3 inflammasome

Laboratory Investigation

Volumn 95, Issue 7, 2015, Pages 804-816

  Wei, Qing ^a,b   Guo, Pengbo ^a   Mu, Kun ^a   Zhang, Ying ^a   Zhao, Wei ^a   Huai, Wanwan ^a   Qiu, Yumin ^a   Li, Tao ^c   Ma, Xiaomin ^a   Liu, Yafei ^a   Chen, Xiaoyan ^a   Han, Lihui ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; ESTRADIOL; ESTROGEN RECEPTOR BETA; INFLAMMASOME; MITOGEN ACTIVATED PROTEIN KINASE; CARRIER PROTEIN; NLRP3 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; CARCINOMA, HEPATOCELLULAR; HEPG2 CELL LINE; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; SIGNAL TRANSDUCTION;

CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; DOWN-REGULATION; ESTRADIOL; ESTROGEN RECEPTOR BETA; FEMALE; HEP G2 CELLS; HUMANS; INFLAMMASOMES; LIVER NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED;

EID: 84933051219     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2015.63     Document Type: Article

References (33)

1. Thomas MB, Jaffe D, Choti MM et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010;28:3994-4005.
2. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001;33:62-65.
3. Kalra M, Mayes J, Assefa S et al. Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. World J Gastroenterol 2008;14:5945-5961.
4. Yeh S-H, Chen P-J. Gender disparity of hepatocellular carcinoma: The roles of sex hormones. Oncology 2010;78:172-179.
5. Naugler WE, Sakurai T, Kim S et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317:121-124.
6. Kuiper GG, Enmark E, Pelto-Huikko M et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93: 5925-5930.
7. Wei Q, Mu K, Li T et al. Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression. Lab Invest 2014;94:52-62.
8. Xu H, Wei Y, Zhang Y et al. Oestrogen attenuates tumour progression in hepatocellular carcinoma. J Pathol 2012;228:216-229.
9. Sander LE, Trautwein C, Liedtke C. Is interleukin-6 a gender-specific risk factor for liver cancer? Hepatology 2007;46:1304-1305.
10. Munding C, Keller M, Niklaus G et al. The estrogen-responsive B box protein: A novel enhancer of interleukin-1beta secretion. Cell Death Differ 2006;13:1938-1949.
11. Cao L, Han L, Zhang Z et al. Involvement of anoikis-resistance in the metastasis of hepatoma cells. Exp Cell Res 2009;315:1148-1156.
12. Zhang Z, Cao L, Li J et al. Acquisition of anoikis resistance reveals a synoikis-like survival style in BEL7402 hepatoma cells. Cancer Lett 2008;267:106-115.
13. Stehlik C, Krajewska M, Welsh K et al. The PAAD/PYRIN-only protein POP1/ASC2 is a modulator of ASC-mediated nuclear-factor-kappa B and pro-caspase-1 regulation. Biochem J 2003;373:101-113.
14. Stehlik C, Lee SH, Dorfleutner A et al. Apoptosis-associated speck-like protein containing a caspase recruitment domain is a regulator of procaspase-1 activation. J Immunol 2003;171:6154-6163.
15. Broz P, von Moltke J, Jones JW et al. Differential requirement for Caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing. Cell Host Microbe 2010;8:471-483.
16. Strowig T, Henao-Mejia J, Elinav E et al. Inflammasomes in health and disease. Nature 2012;481:278-286.
17. Wellington M, Koselny K, Sutterwala FS et al. Candida albicans triggers NLRP3-mediated pyroptosis in macrophages. Eukaryot Cell 2014;13: 329-340.
18. Prieto J. Inflammation, HCC and sex: IL-6 in the centre of the triangle. J Hepatol 2008;48:380-381.
19. Ruggieri A, Barbati C, Malorni W. Cellular and molecular mechanisms involved in hepatocellular carcinoma gender disparity. Int J cancer 2010;127:499-504.
20. Johnson PJ, Krasner N, Portmann B et al. Hepatocellular carcinoma in Great Britain: influence of age, sex, HBsAg status, and aetiology of underlying cirrhosis. Gut 1978;19:1022-1026.
21. Yang W, Lu Y, Xu Y et al. Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs). J Biol Chem 2012;287:40140-40149.
22. Zhang L, Li X, Zhao L et al. Nongenomic effect of estrogen on the MAPK signaling pathway and calcium influx in endometrial carcinoma cells. J Cell Biochem 2009;106:553-562.
23. Lazennec G. Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett 2006;231:151-157.
24. Bossard C, Busson M, Vindrieux D et al. Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer. PLoS One 2012;7:e44787.
25. Yu CP, Ho JY, Huang YT et al. Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-beta activation. PLoS One 2013;8:e56667.
26. Lau KM, LaSpina M, Long J et al. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 2000;60:3175-3182.
27. Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol 2009;55:533-542.
28. Edvardsson K, Strom A, Jonsson P et al. Estrogen receptor beta induces antiinflammatory and antitumorigenic networks in colon cancer cells. Mol Endocrinol 2011;25:969-979.
29. Edvardsson K, Nguyen-Vu T, Kalasekar SM et al. Estrogen receptor beta expression induces changes in the microRNA pool in human colon cancer cells. Carcinogenesis 2013;34: 1431-1441.
30. Wree A, Eguchi A, McGeough MD et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology 2014;59:898-910.
31. Wree A, McGeough MD, Pena CA et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med (Berl) 2014;92:1069-1082.
32. Sagulenko V, Thygesen SJ, Sester DP et al. AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC. Cell Death Differ 2013;20:1149-1160.
33. Aachoui Y, Sagulenko V, Miao EA et al. Inflammasome-mediated pyroptotic and apoptotic cell death, and defense against infection. Curr Opin Microbiol 2013;16:319-326.